Profound Medical Corp. (NASDAQ: PROF)

Profound Medical Corp. is a commercial stage medical device company focused on the development and marketing of AI powered, MRI guided, and incision free therapies for the ablation of diseased tissue. The company’s lead product, the TULSA PRO system, combines real time MRI, robotically driven transurethral sweeping action/thermal ultrasound, and closed loop temperature feedback control to ablate whole gland or physician defined regions of malignant or benign prostate tissue. Its Sonalleve system delivers focused ultrasound from outside the body to treat uterine fibroids, adenomyotic tissue, bone metastases pain, osteoid osteoma, and benign desmoid tumors. Both platforms are designed to work with MRI scanners from Philips, Siemens, and GE Healthcare. The technology incorporates artificial intelligence algorithms to optimize treatment planning and to provide real time feedback during procedures. Profound Medical Corp. pursues additional regulatory clearances and invests in clinical studies to support broader adoption of its incision free ablation platforms.

Profound Medical Corp. generates revenue from the sale of capital equipment, from recurring non capital equipment which includes one time use devices for each patient treated, and from related service and maintenance contracts. The company commercializes its TULSA PRO and Sonalleve systems in the United States, the European Union, and Asia, with revenue mix reported as approximately 76% from the United States, 5% from the EU, and 19% from Asia for the year ended December 31, 2025. Service revenue arises from the sale of disposable procedure kits, from ongoing technical support, and from training and clinical assistance provided to customers. Strategic collaborations with Philips, GE, and Siemens support lead generation and distribution of the capital equipment and help expand the installed base of MRI compatible systems. The company also maintains a direct sales and marketing team that focuses on educating urologists and radiologists about the benefits of its MRI guided ablation technologies.

Profound Medical Corp. competes in the medical device market for minimally invasive ablation therapies against established treatment options such as watchful waiting, active surveillance, simple and radical prostatectomy, external beam radiation therapy, brachytherapy, cryoablation, trans rectal high intensity focused ultrasound, and other focal ablation techniques. The company’s competitive advantages include the TULSA PRO system’s transurethral approach that enables ablation of prostates up to 120 cubic centimeters, millimeter accuracy guided by real time MRI thermometry, and the ability to spare critical structures such as the urethra and rectal wall. Additionally, the Sonalleve system provides a non invasive MRI guided focused ultrasound platform that treats uterine fibroids and bone metastases without ionizing radiation. Regulatory clearances, including FDA 510k clearance for TULSA PRO, CE marking in the EU, and approvals in Canada, China, and South Korea, further strengthen its market position. Profound Medical Corp. holds a broad intellectual property portfolio with approximately 40 patent families representing around 169 granted patents and 29 pending applications worldwide. The company’s technology is designed to be compatible with leading MRI platforms, which facilitates integration into existing hospital workflows and supports its positioning as a preferred partner for advanced imaging centers.

Profound Medical Corp. serves hospitals, independent imaging centers, and urology or radiology practices that adopt its TULSA PRO and Sonalleve systems for prostate and uterine fibroid treatments. The company collaborates with strategic partners Philips, GE, and Siemens to support lead generation and distribution of its capital equipment and to enhance customer access to MRI guided therapy solutions. While no specific end user customer names are disclosed, the physician and institutional base includes leading academic medical centers and community hospitals in the United States, Europe, and Asia. Profound Medical Corp. maintains a direct sales force that engages with opinion leaders in urology and radiology to drive adoption of its incision free ablation platforms. The company’s customers benefit from the ability to offer outpatient procedures with rapid recovery times and reduced reliance on invasive surgical interventions.